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Hepatitis C virus (HCV) is a major leading cause of hepatocellular carcinoma (HCC). HCV-induced hep-
atocarcinogenesis is a multistep process resulting from a combination of pathway alterations that are
either caused directly by viral factors or immune mediated as a consequence of a chronic state of
inﬂammation. Host genetic variation is now emerging as an additional element that contribute to in-
crease the risk of developing HCC. The advent of direct-acting antiviral agents foresees a rapid decline of
HCC rate in HCV patients. However, a full understanding of the HCV-mediated tumourigenic process is
required to elucidate if pro-oncogenic signatures may persist after virus clearance, and to identify novel
tools for HCC prevention and therapy. In this review, we summarize the current knowledge of the
molecular mechanisms responsible for HCV-induced hepatocarcinogenesis. T. Vescovo, CMI 2016;22:853
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatocellular carcinoma (HCC), the ﬁfth most common cancer
in men and the ninth in women, represents an urgent clinical
problem, being the second leading cause of cancer-related death
worldwide (GLOBOCAN 2012, http://globocan.iarc.fr).
Hepatitis C virus (HCV) is a major risk factor for chronic liver
disease and for the increasing HCC incidence in most Western
countries [1]. Approximately 3% of the world population is infected
with HCV, and the severe consequences of virus infection makes
HCV one of the most pressing emergencies worldwide (World
Health Organization, http://www.who.int/).
The majority of infected patients are unable to clear the infec-
tion and develop a chronic hepatitis C (CHC) infection [2]. CHC
results in inﬂammation-induced lesions in the liver frequently
associated with hepatic fat accumulation (steatohepatitis) and
progressive ﬁbrosis, which over 20 to 40 years may evolve in
cirrhosis (10e20% of patients) or HCC (1e5%) (Fig. 1) [3,4]. It iszani’ National Institute for
Rome, Italy.
ia).
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).estimated that 27% of cases of cirrhosis and 25% of HCC cases
worldwide can be attributed to HCV infection [5].
In chronically infected people, the risk of developing HCC is
strictly correlated to ﬁbrosis stage, with the incidence of HCC more
frequent in patients with cirrhotic liver than in those with mild
ﬁbrosis [6]. Moreover, several risk factors, such as hepatitis B virus
or HIV coinfection, obesity, insulin resistance or nonalcoholic
steatohepatitis, actively enhance HCV-related HCC progression [7].
Sustained viral response to interferon (IFN)-based therapies
decreases HCC incidence in a large portion of HCV patients, indi-
cating the importance of eradicating the virus to prevents
tumourigenesis [8,9]. However, despite a successful virus clearance,
the risk of HCC is not fully abrogated in individuals with severe
ﬁbrosis, and continuous HCC surveillance is recommended [10].
The introduction of direct-acting antiviral (DAA) drugs as anti-
HCV therapy, which allows a high rate of virus eradication, will
provide important indications about the effectiveness of virus
clearance in HCC prevention with respect to the disease stage of
HCV patients [11,12].
Hepatocarcinogenesis in HCV-Infected Patients
HCV-related carcinogenesis results from a complex combination
of host, environmental and viral factors. The induction ofof Clinical Microbiology and Infectious Diseases. This is an open access article under
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Fig. 1. HCV-related mechanisms of carcinogenesis: from HCV infection to HCC. Chronic HCV and associated liver cirrhosis represent major risk factors for HCC development.
Hepatocarcinogenesis is a multistep process that may last for years; it involves progressive accumulation of different genetic alterations which lead to malignant transformation.
Malignant transformation of hepatocytes occurs through increased liver cell turnover, induced by chronic liver injury and regeneration, in the context of inﬂammation and oxidative
stress. HCV proteins may directly up-regulate mitogenic pathways, block cell death and induce ROS production. Moreover, HCV triggers persistent inﬂammation with accumulation
of liver-inﬁltrating lymphocytes and production of several cytokines, such as LTa and LTb, which are tightly linked to HCC development. Chronic inﬂammation exacerbates ROS
production, which is considered a main source of genetic mutations. ROS are also associated with TGF-b pathway induction, leading to hepatic stellate cell activation and ﬁbro-
genesis. TGF-b, together with TLR4, plays an important role in the epithelialemesenchymal transition. HCV dysregulates host lipid metabolism, causing liver fat accumulation which
in many patients is associated with HCC. HCV is also able to induce angiogenic and metastatic pathways. Polymorphisms, mainly in DEPDC5 and MICA genes, have been recently
shown to increase the risk of developing HCC. HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ROS, reactive oxygen species; TGF, transforming growth factor.
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direct effect of immune-mediated chronic inﬂammation. However,
HCVmay also directly induce HCC by altering several host regulatory
pathways involved inproliferation, energymetabolism, angiogenesis,
epithelialemesenchymal transition (EMT), DNA repair, apoptosis and
oxidative/endoplasmic reticulum (ER) stress (Fig. 1) [13].
Chronic inﬂammation leads to increased levels of reactive oxy-
gen species (ROS), which damage hepatocytes both at metabolic
and genetic levels, eventually causing cell death. Compensative
liver regeneration, which occurs in a HCV-altered environment,
favours chromosomal instability and irreversible genetic/epige-
netic changes, which promote neoplastic transformation of hepa-
tocytes and the progression of malignant clones [14].
HCV Directly Interferes With Pro- and Antioncogenic
Pathways
Host tumour suppressors and proto-oncogenes are direct tar-
gets of HCV proteins (Fig. 1) [15]. An important example is repre-
sented by the Retinoblastoma (Rb) protein, which is known to
control cell proliferation mainly by repressing the activation of E2F,a transcription factor needed for S-phase entry in the cell cycle [16].
HCV infection in cell culture has been shown to negatively regulate
the levels of Rb [17]. This negative effect is mediated by NS5B,
which binds Rb and promotes its cytoplasmic relocalization and
proteasomal degradation [18,19]. The ﬁnal outcome is the activa-
tion of E2F-responsive genes that stimulate cell cycle progression
[19].
Other HCV proteins are able to stimulate G1/S transition by
activating cyclin/Cdk complexes. NS2 is able to activate cyclin D/
Cdk4 and induce expression of cyclin E [20], while Core increases
the levels of cyclin E and Cdk2 [21], suggesting that HCV has
evolved multiple ways to ensure cell cycle progression [15].
Constitutive activation of growth factor signaling pathways
plays an important role in the initiation and the maintenance of
HCC [22]. HCV Core, E2, NS3 and NS5A stimulate cellular prolifer-
ation by interfering with RAF/MAPK/ERK-regulated pathways,
which are known to be associated with a more aggressive HCC
phenotype [23e26]. The Wnt/b-catenin pathway is also altered by
HCV. This pathway is activated upon binding of Wnt ligands to the
Frizzled receptor and results in the inhibition of b-catenin degra-
dation complex and consequent up-regulation of wide range of
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and cyclin D [27]. Both NS5A and Core have been reported to
activate b-catenin when overexpressed in cell culture through an
indirect mechanism that involves phosphorylation and inactivation
of GSK-3b, and subsequent stabilization of b-catenin [28,29]. More
recent data suggest that b-catenin may also be activated through a
direct interaction with NS5A [30,31]. The functional signiﬁcance of
the activation of b-cateninwithin HCV-infected cells is still unclear.
Although dysregulation of Wnt signaling seems not to be sufﬁcient
of causing malignant transformation of hepatocytes, b-catenin
levels are increased in most HCC and may sustain tumour growth
[22].
An important event in the multistep process of tumourigenesis
is the inhibition of apoptosis, which allows transformed cells to
escape crucial checkpoints during cell cycle. HCV infection has a
complex and incompletely understood interplay with apoptosis.
In cell culture experiments, apoptosis changes as a function of
time, with apoptotic activity being higher in the early stage of
infection and decreasing over time [32]. In patients, excessive
apoptosis is observed in acute and fulminant hepatitis, as well as
with chronic hepatitis. Sustained apoptosis is associated with
persistent inﬂammation and ﬁbrogenesis, while deﬁcient apoptosis
contributes to the development of HCC [33].
The p53 protein is a critical tumour suppressor that coordinates
cell-cycle arrest, senescence and apoptosis [34]. Numerous studies
have indicated that the HCV proteins Core, NS2, NS3 and NS5A
interact with p53 when overexpressed in cell culture [35]. Core
protein directly deregulates the p53 pathway, although contro-
versial results on the consequence on this interaction have been
reported. These discrepancies could be in part dependent on virus
protein concentration, since it was shown that low levels of HCV
Core protein stimulates the transcriptional activity of p53, while
high levels of Core expression repress it [36]. HCV NS2, NS3/4A and
NS5A interfere with the p53 pathway by inducing its relocalization
from nucleus to cytoplasmic/perinuclear regions [20,37,38]. In
particular, the anti-p53 activity of NS5A is mediated by its direct
interaction, which results in the inhibition of p53-induced
apoptosis [39e41].
HCV has evolved mechanisms that antagonize cell death
induced by tumour necrosis factor (TNF)-a, a major apoptotic
cytokine. HCV core protein blocks TNF-a-mediated apoptosis
signaling by inducing the inhibitor FLICE [42]. HCV NS5A protects
against TNF-a mediated apoptotic cell death by blocking the acti-
vation of caspase-3 and inhibiting the proteolytic cleavage of the
death substrate poly (ADP-ribose) polymerase (PARP1) [43,44].
Moreover, NS5A can direct interfere with the apoptotic machinery,
promoting a calpain-mediated proteolysis of Bid, a proapoptotic
member of the Bcl2 family [45].
Transforming growth factor b (TGF-b) signaling is another
important pathway targeted by HCV. TGF-b exerts antiproliferative
and proapoptotic functions, but also have protumoural activities
due to its role in EMT, a process involved in epithelial degeneration,
ﬁbrogenesis, metastatic process and invasiveness [46]. HCV NS5A
has been shown to block TGF-b signaling through direct interaction
with TGF-b receptor I (TGFBR1). NS5A inhibits TGF-b-mediated
phosphorylation and nuclear translocation of Smad2, as well as
Smad3/Smad4 heterodimerization [47]. Moreover, TGF-b pathway
is also a target of HCV core. Interestingly, Pavio et al. [48], by
isolating natural core variants from HCC and their nontumoural
counterparts, showed that tumour-derived core variants inhibit the
TGF-b pathway, while moderate or no effects were observed in the
nontumoural ones. The authors also reported that the inhibition of
TGF-b signaling occurs through a direct interaction with Smad3,
which results in the inhibition of the DNA-binding activity of the
Smad3/4 complex. These data suggest that during chronic infection,virus variants are selected to favour cell transformation by
providing resistance to TGF-b antiproliferative effects. Relevant to
this regard is the observation of Battaglia et al. [49] showing that
HCV may interfere with the antitumoural effect of TGF-b, without a
signiﬁcant impact on EMT. They found that the expression of HCC-
derived HCV core proteins renders primary human or mouse he-
patocytes less responsive to tumour suppressive effects of TGF-b by
reducing Smad3 signaling. However, the residual activity of Smad3
is sufﬁcient to sustain the pro-EMT activity of TGF-b, which may
contribute to HCC progression.
Related to the dual role of TGF-b in cancer, it was observed that,
in HCV-infected patients, chronic inﬂammation shifts the TGF-b
activity from tumour-suppressor to ﬁbrogenic, thus increasing the
risk for HCC. In particular, a phosphorylation of Smad3 mediated by
c-Jun N-terminal kinase (JNK), different from that performed by
classical TGFBRI pathway, promotes extracellular matrix deposition
by up-regulating plasminogen activator inhibitor 1 (PAI-1), and is
expressed during disease progression from chronic hepatitis
through cirrhosis and HCC [50].
Furthermore, HCV may indirectly inhibit apoptosis by stimu-
lating the PI3K-Akt survival pathway. In particular, this effect ap-
pears to bemediated by NS5A, which is able to down-regulate PTEN
and relieves its inhibitory effect on PI3K-Akt pathway [51].
Another important survival pathway modulated by HCV is
autophagy, a process that may play either anti- or protumour
functions in the early and late phases of carcinogenesis [52,53].
Defective autophagy in mice results in spontaneous development
of HCC. This is mainly due to accumulation of the autophagy cargo
p62 and the consequent persistent activation of the transcription
factor Nrf2, which regulates the expression a variety of cytopro-
tective genes [54,55]. Moreover, autophagy deﬁciency in hepato-
cytes has been also shown to favour EMT [56]. On the other hand,
autophagy stimulation may promote the growth of early preneo-
plastic liver nodules in a Resistant-Hepatocyte rat model [57].
Autophagy is induced by HCV infection, playing important roles in
the control of virus replication/secretion, inﬂammation and lipid
homeostasis [58e63]. Interestingly, recent studies indicate that p62
levels are increased in HCV-induced HCC, suggesting that the
impairment of autophagy may play a role in tumour development
[64,65].
Other alterations caused by HCV infection that may affect the
development of HCC are related to the dysregulated production of
ROS. There are many reports describing elevated ROS levels in HCV
replicating cells and in liver tissue from HCV-infected patients
[66,67]. Mitochondria are considered the major site for the pro-
duction of ROS in HCV-infected cells [68]. HCV core protein affects
the release of ROS from mitochondria because of its association
with mitochondrial membranes, where it alters the electron
transport chain and the antioxidant enzyme systems [69e71].
NS5A plays also a role in the production of ROS, since its over-
expression induces calcium release from ER, which is quickly
absorbed by mitochondria, resulting in an elevation of ROS [72,73].
The presence of high levels of ROS due to unbalanced oxidative
stress are known to favour the development of HCC by directly
modifying mitochondrial and nuclear DNA, which during the
repairing process may result in gene mutation [74].
Role of Immune-Mediated Liver Alterations in HCV-Induced
HCC
To establish a chronic infection, HCV deregulates both innate
and adaptive immunity through multiple mechanisms, including
inhibition of type I IFN production and alteration of CD4 T cell
differentiation towards unfavourable Th2, Th17 and regulatory T
cells (Treg) subsets, which impairs the function of cytotoxic
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alterations result in a low-grade chronic liver inﬂammation that
persistently perturbs tissue homeostasis and promotes a procarci-
nogenic environment inducing the release of ROS, nitric oxide
species, lipid peroxidation and aberrant expression of cytotoxic
cytokines [79]. At the same time, this condition may favour the
impairment of immune surveillance and consequently the immune
escape of neoplastic transformed cells, thus contributing to HCC
development [80].
Many inﬂammatory cytokines, including TNF-a, interleukin (IL)-
1, IL-23, IL-6 and lymphotoxins (LT) a and b have been implicated in
chronic liver inﬂammation and HCC progression (Fig. 1) [80e82]. In
particular, HCV-related hepatocarcinogenesis appears to be
dependent on a delicate balance between pro- and anti-
inﬂammatory stimuli. A high ratio of TNF-a/IL-10 levels has been
observed in sera from patients with severe liver damage and HCC
[83]. Moreover, the protumoural role of inﬂammatory cytokines,
such as IL-6, seems to be dependent on the presence of estrogen. In
fact, serum levels of IL-6 are higher in CHC patients than in healthy
controls, but only female patients display an increased risk of HCC
development [81].
Among inﬂammatory cytokines, evidence points at an
important role of LTa and LTb in the development HCC [82].
Notably, liver-speciﬁc overexpression of LTa and LTb in mice leads
to high inﬂammation levels accompanied by severe hepatotox-
icity and spontaneous HCC development [82]. Experimental data
point to the activation of NF-kB pathway by LTs as the triggering
event of hepatocarcinogenesis by causing an ampliﬁcation in the
production of chemokines and cytokines, which trigger hepatic
cell death, tissue remodelling and cell malignant transformation
[82]. Severe liver damages induced by high expression of LTs
correlate with an increased numbers of liver-inﬁltrating lym-
phocytes [82].
During HCV infection, liver-inﬁltrating lymphocytes fail virus
clearance and accumulate in the liver, contributing to establish
chronic inﬂammation [82,84]. Notably, Ramzan et al. [84] have
observed the presence of higher levels of liver-inﬁltrating T and B
cells in cirrhotic parenchyma of HCV infected patients with HCC
compared to HCV patients without HCC. In particular, a high
number of CD8þ T cells in cirrhotic areas, but not in tumour of
HCV-HCC patients, correlates with HCC occurrence and is a
prognostic factor for recurrence after surgical resection [84].
Moreover, in HCV patients with HCC, an increased number of in-
ﬂammatory CD8þ cells is accompanied by a decrease of NK and
NKT cells, which are known to participate in cancer immuno-
surveillance [84]. In contrast, an accumulation of T-reg cells, key
suppressors of antitumour immunity, has been described in both
HCC and cirrhotic tissue of HCV-infected patients [85]. Altogether,
these data indicate that the synergistic effect of tumour-
promoting inﬂammation and impaired anticancer immunity
may be crucial in the progression from HCV-related cirrhosis to
HCC.
Steatohepatitis and Hepatic Fibrosis in HCC
HCV-related HCC is frequently accompanied by steatohepatitis,
suggesting that alteration of lipid metabolism, associated with
inﬂammation, may take part to the multistep process of carcino-
genesis [86]. It is well established that HCV proteins interfere with
host lipid metabolism, mainly resulting in lipogenic pathways
activation and decreased lipid catabolism, and consequently may
trigger lipotoxicity in infected cells [62,87]. Indeed, an accumula-
tion of free fatty acids is responsible for the production of ROS as a
consequence of mitochondrial dysfunctions and ER stress. Oxida-
tive stress can in turn stimulate lipid peroxidation and activate,over a certain threshold, an inﬂammatory cascade culminating in
the release of several inﬂammatory cytokines, such as TNF-a and IL-
1, which are intimately implicated in the development of steato-
hepatitis and insulin resistance [88]. Increased ROS levels have also
a direct impact on ﬁbrosis, by stimulating collagen I expression
[89], and on genome abnormalities, by favouring gene mutations
and chromosomal instability [90e92].
Accordingly, high expression levels of lipogenic genes have been
reported in clinical HCC samples [93]. Moreover, in patients with
chronic HCV, the administration of statins has been associated with
a dose-dependent reduction in incident cirrhosis and HCC [94],
conﬁrming an intimate relationship between steatosis and HCC. In
line with this idea, obesity and diabetes represent dangerous risk
factors for HCC progression in chronically HCV-infected patients
[95].
A novel mechanism by which HCV and obesity may synergize in
inducing HCC has been recently proposed. Mice expressing HCV
NS5A in the liver develop HCCwhen fedwith alcohol and/or a high-
fat diet in a TLR4-dependent manner [96,97]. Notably, NS5A, by
increasing the levels of TLR4, ampliﬁes the induction of the stem
cells transcription factor NANOG stimulated by circulating endo-
toxins, thus generating tumour-initiating stemlike cells (TIC). They
also found that NANOG promotes tumourigenesis by inducing
Twist1, a master regulator of EMT, in cooperation with the
adipocyte-derived leptin-pSTAT3 pathway, as well as by activating
fatty acid oxidation to support TIC self-renewal and drug resistance
[97,98].
An important aspect in the pro-HCC characteristics of HCV-
induced steatosis is the alteration of liver T cell function. Trans-
genic mice, constitutively expressing HCV proteins in the liver,
develop, with age, extensive steatosis which is accompanied by a
consistent T cell inﬁltrate made up predominately of CD8þ T cells
secreting Th2-type cytokines [99]. More recently, in a mouse model
of combined steatohepatitis and obesity, it has been observed that
the massive liver inﬁltration and the activation of CD8þ and NKT
cells are required to induce steatosis, inﬂammation and carcino-
genesis [100]. Moreover, a direct link was found between increased
lipid production, in particular linoleic acid, and selective CD4þ T
cells loss in obesity-induced mice, which enhances HCC develop-
ment by impairing antitumour immunity [101]. Altogether, these
data emphasize the controversial and crucial role of immune sys-
tem in HCV-related HCC development, indicating the importance of
developing a targeted immune-based treatment approach for
curing HCC [102].
In HCV-infected patients, an increasing risk of HCC onset is also
tightly correlated with the severity of liver ﬁbrosis. Speciﬁcally,
proﬁbrogenic cytokines have been also identiﬁed as key modula-
tors of HCC progression [50]. TGF-b is a crucial cytokine involved in
ﬁbrogenesis, whose expression is induced directly by HCV core
protein or through oxidative/ER stress and NF-kB pathway activa-
tion (Fig. 1) [103e106]. High levels of TGF-b have been observed
both in serum and liver tissue of chronic HCV infected patients
[107,108], as well as in patients with HCC [109]. Although Kupffer
cells and liver-inﬁltrating lymphocytes are in large part responsible
for TGF-b release [92], hepatocytes have been also identiﬁed as a
source [103e105]. Recently Jee et al. [110] have shown that hepa-
tocytes of HCV-infected patients express high levels of TGF-b and,
in vitro, the amount of secreted TGF-b is sufﬁcient to activate he-
patic stellate cells. Upon stimulation, quiescent hepatic stellate cell
transdifferentiate in myoﬁbroblast and initiate to release proﬁ-
brogenic mediators, inﬂammatory cytokines and chemokines,
exacerbating liver inﬂammation and ﬁbrogenesis [111]. In addition
to its ﬁbrogenic property, TGF-b also acts as immunosuppressor,
thus favouring the immune escape of neoplastic transformed cells
[112].
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Neoangiogenesis is an essential step for the growth and the
survival of cancer cells. Many studies have shown that among all
cases of HCC, microvessel density is higher in HCV-positive patients
[113,114].
Experimental data suggest that structural and nonstructural
HCV proteins could play a direct role in the induction of this process
(Fig. 1). HCV core protein promotes angiogenesis by up-regulating
hypoxia inducible factor Ia [115], which transcriptionally up-
regulates vascular endothelial growth factor (VEGF) [116] and
cyclooxygenase 2, as well as by activating matrix metal-
loproteinases, such as MMP-2 and MMP-9 [117]. VEGF has been
reported to be an important endothelium-speciﬁc growth factor in
HCC [118,119]. For this reason, serum levels of VEGF are used as
prognostic factor of HCC [120e122]. Angiopoietin-2 (Ang2) was
also shown to be up-regulated by HCV infection [123]. Ang2, with
the receptor Tie-1, controls vessel quiescence. Under VEGF stimu-
lation, Ang2 could be released from the endothelial cells and pro-
mote the proangiogenic action of VEGF.
Neoangiogenesis is not only required for tumour cell survival but
also allowsmalignant cells to spread through the neovascularization
and lead to intrahepatic and extrahepatic metastasis. The portal
tract ofHCC lesions is theﬁrst site of intrahepaticmetastasis because
cancer cells enter the portal vein via efferent ﬂow [124].
A central role in the metastatic process is played by EMT, a
process through which epithelial cells acquire mesenchymal char-
acteristics, displace the tight and adherens junction components
and increase cellular motility and invasion [125]. Notably, NS5A has
been reported to trigger EMT through activating Twist2, a key
transcriptional regulator of this process [126]. An alternative EMT
induction pathway is triggered by E1/E2 proteins and uses TGF-b
and VEGF signaling. TGF-b and VEGF are also regulated by HIF-1a,
which, as previously described, is up-regulated by HCV core protein
and increases hepatoma migration and permeability [127].
Role of Host and Virus Genetic Factors in HCV-Related HCC
Several gene mutations have been associated with hep-
atocarcinogenesis [128]. The ﬁrst identiﬁed gene was the tumour
suppressor gene p53, themutation of whichmay lead to either gene
inactivation or the production of dominant-negative forms [129].
The use of whole-genome sequencing has now provided a more
detailed picture of genetic alteration in HCC, identifying a subset of
genes more frequently mutated in HCV patients [130]. In particular,
a high rate of mutations (>30%) was found in the oncogene CTNNB1,
which encodes the b-catenin protein of the Wnt signaling pathway
[131e133]. Another frequent genetic alteration detected in HCC
regards the telomerase reverse transcriptase (TERT) gene, often
involving its promoter region, which results in an increased
expression of this pro-oncogenic factor (Fig. 1) [134e136].
Besides mutations in tumour suppressor genes, recent evi-
dences indicate that host genetic variants are associated with a
higher risk of HCC development [137]. Next-generation sequencing
technology has been extensively applied to in-depth analysis of
genetic variations in HCV patients.
An interesting example is represented by the IFNL3/4 genes, two
members of the IFN-l cytokine family in which variants are known
to be strongly associated with HCV patient response to therapy and
natural clearance of infection [138]. Of note, one of these poly-
morphisms, which is located in the 30 untranslated region of IFNL3
mRNA, dictates transcript stability by inﬂuencing the binding of
microRNAs (miRNAs) that are induced by HCV infection [139]. The
IFNL3 unfavourable polymorphisms have been also associated withan increased risk for HCC, especially in patients without a sustained
viral response, although a series of validation studies failed to
detect this association [140e144].
Similar incongruous observations has been reported for the
PNPLA3 gene (patatin-like phospholipase domain-containing pro-
tein 3), which shows a signiﬁcant association with the presence of
nonalcoholic fatty liver disease in HCV patients, while either posi-
tive or negative results were obtained concerning the relation to
higher HCC risk [144e148].
Polymorphisms in other cytokines and/or related receptors have
been found to be associated with HCC. Variants were identiﬁed in
two main actors of the inﬂammatory response against HCV: the
proinﬂammatory cytokine TNF-a and the anti-inﬂammatory cyto-
kine IL-10. Patients carrying low-production haplotypes of IL-10
and TNF-a 308 GG genotype have a higher risk of developing HCC
[149]. Moreover, a rare variant of IL-23R was observed to correlate
with reduced risk of HCV-related HCC in Egyptian patients [150].
Also, a HCC-associated polymorphism was found in the VEGF gene,
which correlates with higher VEGF expression levels [122].
Recent genomewide association studies in large Japanese co-
horts identiﬁed genetic variants in DEPDC5 and MICA (MHC class I
polypeptide-related sequence A) genes that are associated with
HCV-related HCC [151,152]. While DEPDC5 function is still un-
known,MICA is a plasma membrane protein that is required for the
binding to NK group 2D (NKG2D) cells and mediates their cytotoxic
activity towards target cells in tumour immune surveillance. Un-
expectedly, a validation study on a Caucasian cohort found that the
same polymorphism has a protective impact on HCC development,
while no associationwas observed for DEPDC5. Moreover, the study
identiﬁed a novel variant in the HCP5 gene located upstream of
MICA as a stronger predictor of HCC [153]. Further validation ana-
lyses in different ethnic populations will help to deﬁne the pre-
dictive value of these markers.
Variations at the level of HCV sequence could also inﬂuence the
risk of developing HCC. Polymorphisms of Core, NS3 and NS5A in
circulating HCV genotype 1b and Core in genotype 1a have been
reported to be associated with the development of HCC [154,155].
HCV sequences were recently compared between tumoural and
nontumoural tissues; this analysis revealed a signiﬁcant decrease of
HCV levels in transformed cells and the presence of different qua-
sispecies in the two districts, suggesting segregation of speciﬁc
virus variants in HCC [156].
Epigenetic Alterations in HCV-Related HCC
Epigenetic regulatory genes are also dysregulated in HCC, which
can result in a profound and permanent modiﬁcation of gene
expression [157]. An example is represented by the histoneelysine
N-methyltransferase enzyme EZH2, which is aberrantly expressed
in HCC [158] and also targets, among many genes, the expression of
tumour suppressor miRNAs [159,160].
Another epigenetic-related modiﬁcation observed during HCV
infection is the inhibition of histone H4 arginine methyltransferase
1 (PRMT1), which is associated with the virus-mediated up-regu-
lation of protein phosphatase 2A (PP2Ac) [161].
Changes in gene methylation were also correlated with virus-
induced tumours [162]. In particular, a variety of tumour suppres-
sor genes, including CDKN2A, GSTP1, RUNX3, APC, SOCS-1 and
RASSF1A are highly methylated in HCC from hepatitis B virus and
HCV [163e166]. From a mechanistic point of view, a major role in
DNAmethylation changes is played by the HCV core protein. In fact,
HCV core protein has been reported to inhibit the expression of the
CDKN2A gene, which encodes for p16INK and p14Arf, two inhibitors
of cell proliferation, by up-regulating the methyltransferases
T. Vescovo et al. / Clinical Microbiology and Infection 22 (2016) 853e861858DNMT1 and DNMT3b [167]. Moreover, HCV core protein also in-
creases the methylation of RASSF1A promoter, a negative regulator
of the Ras pathway, by inducing the histone methyltransferase
SMYD3 (SET and MYND domain containing 3) [168].
Epigenetic alterations relevant for HCC may be mediated by
changes in miRNA and long noncoding RNAs. A variety of miRNAs
have been reported to modulate HCV replication in a positive or
negative manner [169]. One of the most characterized HCV-related
miRNA is miR-122, a liver-speciﬁc human miRNA that is highly
expressed, that could pair to the 50 untranslated region of HCV
genomic RNA and enhance the virus replication within liver cells
[170]. Less characterized is the role of miRNA in hepatocarcino-
genesis. Some of miRNAs (miR-122, miR-27a and miR-181c)
involved in the inhibition of proliferation, lipid metabolism and
hepatocyte growth are down-regulated in HCV-related HCC, while
others (miR-21, mi-R-221, miR-130a, Let7b, miR-155 andmiR-200c)
that regulate metabolism and immune response have been found
to be up-regulated [60,171,172]. Recently up-regulation of miR-200c
and miR-21 have been linked to hepatic ﬁbrosis in HCV patients
[169]. Because a relation between serummiR-122 levels and clinical
features in HCV patients has been observed, it will be interesting to
analyse whether miR-122 or other miRNAs may also serve as
circulating biomarkers of HCC [173].
Conclusion
Our understanding of how HCV triggers HCC by direct and in-
direct mechanisms has signiﬁcantly improved. In particular, new
insights on the interrelation between HCV-induced alterations of
immune cell activity and the development of HCC are promising to
provide, in the near future, novel tools to monitor the progression
of liver disease to HCC and to stimulate an effective anticancer
immunity. Moreover, it is foreseeable that the ongoing identiﬁca-
tion of genetic and epigenetic factors associated with HCC will help
to identify HCV patients at higher risk.
In the next years, current DAA therapeutic strategies, which
have high sustained viral response rates in both patients with
compensated and decompensated cirrhosis, are expected to
prevent the progression of HCV-related pathologies, including
HCC [174]. A ﬁrst study on HCV-infected patients with advanced
cirrhosis conﬁrmed this expectation, showing a signiﬁcant
improvement of liver function (Model for End Stage Liver Disease
(MELD) score) when DAA therapies are successful [175]. More
recently, a study on HCV-infected patients treated with sofos-
buvir reported a signiﬁcant reduction in liver ﬁbrosis when
monitored by serologic and ultrasound-based tests [176]. A
further important result observed with DAA is the reduction in
recurrence of HCV infection in patients with HCC after liver
transplantation [177]. However, in apparent contrast with this
observation, a recent study on HCV patients with HCC undergoing
chemotherapy and successful IFN-free DAA treatment revealed a
high rate of early HCC recurrence, suggesting a negative effect of
DAA on tumour immunosurveillance, possibly due to decreased
levels of inﬂammation observed after HCV clearance [178]. If the
negative impact of DAA on antitumoural immunity is conﬁrmed,
it will be important to evaluate if DAA-mediated HCV clearance
also inﬂuences the progression of preneoplastic lesions and if
immunotherapies may compensate for the decreased ‘beneﬁcial’
inﬂammatory state.
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